07/10/2024
Key points:
With BBSRC investment through the ALERT programme, the Institute’s Flow Cytometry facility has expanded its provision of spectral flow cytometry with the acquisition of a Becton Dickinson FACSDiscover S8 Spectral Sorter (S8). The cell sorter is the first instrument within the facility that can pair cell sorting with cell imaging, allowing researchers to identify and obtain cell populations that could not previously be isolated.
The Institute’s Flow Cytometry facility provides an unmatched provision of technology and expertise to researchers at the Institute, on the Babraham ¶¶Òõ¶ÌÊÓƵ Campus and nationally. The addition of combined cell sorting and cell imaging capability extends how the facility is able to support cutting-edge research, enabling new science to support improved health.
Dr Rachael Walker, Head of the Flow Cytometry facility, described the potential of the new instrument: “In recent years we have led the application of spectral flow cytometry and seen this technology enthusiastically embraced by the Institute’s researchers. The new instrument overcomes a significant limitation of our current cell sorting provision, allowing users to sort cells based on their morphology or fluorescence characteristics for the first time. This insight into cell populations will be transformative for the research we support.â€
Transforming research
With wide uptake of the new S8 instrument across the Institute’s three research programmes, use of the S8 by Institute researchers in particular will:
Flow cytometry technology is an essential component of the Institute’s life science research. The facility, recognised as an internationally-leading hub for spectral and imaging cytometry, also supports over 30 commercial life science companies on the Babraham ¶¶Òõ¶ÌÊÓƵ Campus as well as from the Cambridge and Stevenage bioclusters.
With its cutting-edge and bespoke approach to flow cytometry applications, the facility’s expert team work hand in hand with researchers from concept development to data acquisition and analysis.
Dr Andrea Negro, EMEA Product Manager, said: “We are sure that the dynamic scientific community at the Institute and on the Babraham ¶¶Òõ¶ÌÊÓƵ Campus will leverage the innovative technology of the S8 to deliver groundbreaking research in the near future. With support from the facility’s expert team, users will immediately benefit from the SpectraFX(TM) system, while discovering what's behind the dots exploring the CellView(TM) Image Technology potential.â€
Supporting skills development
Facility members are active in international networks to share and extend best practice and the facility runs the UK’s only spectral flow cytometry symposium as well as a successful training programme. Participants at the Institute’s recent Spectral Flow Cytometry symposium were amongst the first to experience the capabilities of the new instrument and the S8 will also be included in the team’s future training on spectral cytometry and cell sorting.
The facility team works in close partnership with companies developing flow cytometry technology to provide expert feedback on requirements. The relationship established between the facility and Becton Dickinson has also resulted in guidance for the flow cytometry field on practical considerations for buffers for spectral cell sorting (Dapaah et al. 2024, ).
ALERT 2023
Aligning with UKRI’s people and teams action plan, applications to the ALERT programme could be led by research technical professionals (in contrast to the usual requirement for grant applications to be led by Principal Investigators). The Institute’s application was led by the Head of the Flow Cytometry facility, Dr Rachael Walker.
Overall, the ALERT 2023 investment from the BBSRC totalled £22.3m, supporting 29 projects in 22 organisations across the UK.
Find out more about the facility’ capabilities and training
Institute’s Spectral Flow Cytometry Symposium goes from strength to strength
PlaqueTec and the Babraham Institute collaborate on blood screen to improve treatment for coronary artery disease
07 October 2024